Drug intelligence / Profile preview

derenofylline

Development stage: Phase 2
Lead developer: Abbott
Modality: Small Molecules

Overview

Derenofylline is a small molecule drug that acts as an antagonist of the adenosine A1 receptor. It was investigated for the treatment of acute decompensated heart failure. As an adenosine A1 receptor antagonist, its mechanism involves blocking the action of adenosine at this receptor subtype, which may have beneficial effects in conditions where adenosine-mediated signaling contributes to disease pathology. Derenofylline reached Phase 2 clinical trials for acute decompensated heart failure but development was discontinued[10].

Other names: derenofylline

Targets

ADORA1 (Adenosine receptor A1 subtype)

Beyond the preview

Go deeper on derenofylline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on derenofylline.

Explore the full profile